Abstract
MUTYH-associated polyposis (MAP) is an autosomal recessive disorder where the inheritance of constitutional biallelic pathogenic MUTYH variants predisposes a person to the development of adenomas and colorectal cancer (CRC). It is also associated with extracolonic and extraintestinal manifestations that may overlap with the phenotype of familial adenomatous polyposis (FAP). Currently, there are discrepancies in the literature regarding whether certain phenotypes are truly associated with MAP. This narrative review aims to explore the phenotypic spectrum of MAP to better characterise the MAP phenotype. A literature search was conducted to identify articles reporting on MAP-specific phenotypes. Clinical data from 2109 MAP patients identified from the literature showed that 1123 patients (53.2%) had CRC. Some patients with CRC had no associated adenomas, suggesting that adenomas are not an obligatory component of MAP. Carriers of the two missense founder variants, and possibly truncating variants, had an increased cancer risk when compared to those who carry other pathogenic variants. It has been suggested that somatic G:C>T:A transversions are a mutational signature of MAP, and could be used as a biomarker in screening and identifying patients with atypical MAP, or in associating certain phenotypes with MAP. The extracolonic and extraintestinal manifestations that have been associated with MAP include duodenal adenomas, duodenal cancer, fundic gland polyps, gastric cancer, ovarian cancer, bladder cancer and skin cancer. The association of breast cancer and endometrial cancer with MAP remains disputed. Desmoids and Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPEs) are rarely reported in MAP, but have long been seen in FAP patients, and thus could act as a distinguishing feature between the two. This collection of MAP phenotypes will assist in the assessment of pathogenic MUTYH variants using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) Variant Interpretation Guidelines, and ultimately improve patient care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH grant number U24CA258119 (PI Marc Greenblatt). John-Paul Plazzer was also supported by a subaward of this grant and by the Alan Watt and Chris Geyer Oncology Fellowship through The Royal Melbourne Hospital Foundation. Gabriel Capella is supported by the Spanish Ministry of Science and Innovation, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant (PID2019-111254RB-I00/ DOI: 10.13039/501100011033). This study was also supported by CIBERONC (CB16/12/00234) and IMP/00009 financed by the Instituto de Salud Carlos III (ISCIII) and Fondo Europeo de Desarrollo Regional (FEDER).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://doi-org.ezproxy.uvm.edu/10.1016/S0140-6736(03)13805-6 https://doi.org/10.1136/jmg.2005.033217 https://doi.org/10.1002/ijc.20054 https://doi.org/10.1002/ijc.21905 https://doi.org/10.1056/NEJMoa025283 https://doi.org/10.1053/j.gastro.2004.03.070 https://doi.org/10.1016/j.canlet.2008.04.004 https://doi.org/10.1016/j.cgh.2006.12.025 https://doi.org/10.1093/jnci/djh288 https://doi.org/10.1053/j.gastro.2009.08.052 https://doi.org/10.1053/j.gastro.2004.02.022 https://doi.org/10.1002/humu.9282 https://doi.org/10.1111/j.1399-0004.2010.01528.x https://doi.org/10.1053/j.gastro.2008.10.056 https://doi.org/10.1158/1078-0432.CCR-13-1490 https://doi.org/10.1111/j.1399-0004.2009.01241.x https://doi.org/10.1136/gut.2007.145748 https://www.research.ed.ac.uk/en/publications/carcinogenesis-in-myh-associated-polyposis-follows-a-distinct-gen https://doi.org/10.1111/codi.15078 https://doi.org/10.1002/ijc.21470 https://doi.org/10.1016/S1542-3565(05)00411-8 https://doi.org/10.1111/j.1399-0004.2010.01478.x https://doi.org/10.1016/j.cgh.2006.01.005 https://doi.org/10.1089/gte.2007.9995 https://doi.org/10.1016/j.cgh.2016.02.020 https://doi.org/10.1053/j.gastro.2020.10.038 https://doi-org.ezproxy.uvm.edu/10.1007/s10689-020-00162-9 https://doi.org/10.1016/S0002-9440(10)63443-8 https://doi.org/10.1086/431213 https://doi.org/10.1001/jama.2012.8780 https://doi.org/10.1002/ijc.20983 https://doi-org.ezproxy.uvm.edu/10.1007/s00384-007-0289-8 https://doi-org.ezproxy.uvm.edu/10.1245/s10434-008-0297-0 https://doi.org/10.1016/j.mrfmmm.2005.01.017 https://doi-org.ezproxy.uvm.edu/10.1007/s10689-018-00116-2 https://doi.org/10.1111/j.1399-0004.2008.00998.x
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the Supplementary section of the manuscript.
List of abbreviations
- ACMG
- American College of Medical Genetics and Genomics
- AMP
- American Association of Molecular Pathology
- APC
- Adenomatous Polyposis Coli
- BER
- Base Excision Repair
- CHRPE
- Congenital Hypertrophy of the Retinal Pigment Epithelium
- CRC
- Colorectal Cancer
- FAP
- Familial adenomatous polyposis
- HP
- Hyperplastic Polyps
- MAP
- MUTYH-associated polyposis
- MMR
- Mismatch Repair
- SIR
- Standardized Incidence Ratio
- SSL
- Sessile Serrated Lesions
